Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.02 is 66% below its 5-year average of 0.07, around the middle of its 5-year range (-0.10–0.17).
As of the fiscal period ended Tuesday, June 30, 2026. 21.23% above its 12-month average of 0.02.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.02.
DEBT TO EQUITY RATIO
0.02
DEBT TO EQUITY RATIO AVG TTM
0.02
DEBT TO EQUITY RATIO AVG 3Y
0.04
DEBT TO EQUITY RATIO AVG 5Y
0.07
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+21.23%
CURRENT VS 3Y AVG
-40.41%
CURRENT VS 5Y AVG
-65.82%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 533 covered companies
CURRENT VS SECTOR MEDIAN
-81.33%
vs the sector median at left
Kalaris Therapeutics Inc
Market Cap
$63.18M
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.04
5Y Avg
0.07
Market Cap
$64.35M
Debt to Equity Ratio
21.48
TTM Avg
9.81
3Y Avg
10.71
5Y Avg
5.89
Market Cap
$64.47M
Debt to Equity Ratio
N/A
TTM Avg
5.13
3Y Avg
7.62
5Y Avg
5.19
Market Cap
$65.15M
Debt to Equity Ratio
N/A
TTM Avg
1.49
3Y Avg
1.10
5Y Avg
0.74
Market Cap
$67.43M
Debt to Equity Ratio
0.39
TTM Avg
2.42
3Y Avg
2.91
5Y Avg
2.20
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $63.18M | 0.02 | 0.02 | 0.04 | 0.07 |
| Alps Group Inc (ALPS)vs › | $64.06M | N/A | 0.32 | 0.11 | 0.11 |
| Heron Therapeutics, Inc. (HRTX)vs › | $64.35M | 21.48 | 9.81 | 10.71 | 5.89 |
| Gossamer Bio, Inc. (GOSS)vs › | $64.47M | N/A | 5.13 | 7.62 | 5.19 |
| InterCure Ltd. (INCR)vs › | $64.68M | 0.46 | 0.49 | 0.48 | 0.36 |
| PDS Biotechnology Corporation (PDSB)vs › | $65.15M | N/A | 1.49 | 1.10 | 0.74 |
| Cingulate Inc. (CING)vs › | $66.16M | 0.27 | 2.09 | 1.90 | 1.47 |
| Adicet Bio, Inc. (ACET)vs › | $59.64M | 0.11 | 0.09 | 0.09 | 0.11 |
| Fortress Biotech, Inc. (FBIO)vs › | $67.43M | 0.39 | 2.42 | 2.91 | 2.20 |
| Fractyl Health, Inc. (GUTS)vs › | $58.71M | N/A | 4.36 | 4.36 | 3.25 |
Debt/Equity
0.02
Current Ratio
10.98
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.02 |
| 2026-03-31 | 0.02 |
| 2025-12-31 | 0.02 |
| 2025-09-30 | 0.04 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | -0.10 |
| 2024-06-30 | 0.07 |
| 2024-03-31 | 0.15 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.17 |
| 2023-06-30 | 0.14 |
| 2023-03-31 | 0.17 |
| 2022-12-31 | 0.16 |
| 2022-09-30 | 0.09 |
| 2022-06-30 | 0.14 |
| 2022-03-31 | 0.12 |
| 2021-12-31 | 0.13 |
| 2021-09-30 | 0.12 |
| 2021-06-30 | 0.03 |
| 2021-03-31 | 0.03 |
| 2020-12-31 | 0.02 |
| 2020-09-30 | 0.03 |
| 2020-06-30 | 0.10 |
| 2020-03-31 | 0.10 |
| 2019-12-31 | 0.10 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
